eGFRcr-cys Levels More Strongly Linked to Adverse Outcomes in Seniors
29 Jan 2024
Clinical ResultClinical Study
MONDAY, Jan. 29, 2024 -- In older patients, a low estimated glomerular filtration rate (eGFR) based on creatinine and cystatin C levels (eGFRcr-cys) is more strongly associated with adverse outcomes compared with low eGFR based on creatinine level (eGFRcr), according to a study published online Jan. 30 in the Annals of Internal Medicine.
Edouard L. Fu, Ph.D., from the Karolinska Institute in Stockholm, and colleagues note that the commonly accepted threshold of GFR to define chronic kidney disease (CKD) is 2 and is based partly on the associations between eGFR and the frequency of adverse events, which are weaker in older adults. The authors assessed associations between eGFRcr versus eGFRcr-cys and eight outcomes in older adults. Data were included for 82,154 participants aged 65 years and older with outpatient creatinine and cystatin C testing.
The researchers observed monotonic associations between eGFRcr-cys and outcomes, while most associations for eGFRcr were U-shaped. Compared with eGFRcr, eGFRcr-cys was more strongly associated with outcomes. The adjusted hazard ratios (95 percent confidence intervals) for all-cause mortality were 1.2 (1.1 to 1.3) and 1.0 (0.9 to 1.0) for eGFRcr-cys and eGFRcr, respectively, for 60 versus 80 mL/min/1.73 m2, and 2.6 (1.2 to 5.8) and 1.4 (0.7 to 2.8), respectively, for kidney failure with replacement therapy. In subgroups, including those with a urinary albumin-creatinine ratio below 30 mg/g, the findings were similar.
"The broad range of risks associated with CKD at older age is better appreciated when cystatin C is included in GFR estimation," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.